Cover Image

HARDBACK
$52.95



View/Hide Left Panel
  • rheumatoid arthritis therapeutic vaccine,

  • Group B streptococcus vaccine to be well-incorporated into routine prenatal care and administered to women during first pregnancy and to high-risk adults (at age 65 years and to people less than age 65 years with serious, chronic health conditions), and

  • Streptococcus pneumoniae vaccine to be given to infants and to 65-year-olds.

Nine candidate vaccines fall into the more favorable (II) category: those with which a vaccination strategy would incur small costs (less than $10,000) for each QALY gained. The Level II vaccine candidates are as follows (in alphabetical order):

  • chlamydia vaccine to be administered to 12-year-olds,

  • Helicobacter pylori vaccine to be administered to infants,

  • hepatitis C virus vaccine to be administered to infants,

  • herpes simplex virus vaccine to be administered to 12-year-olds,

  • human papillomavirus vaccine to be administered to 12-year-olds,

  • melanoma therapeutic vaccine,

  • Mycobacterium tuberculosis vaccine to be administered to high-risk populations,

  • Neisseria gonorrhea vaccine to be administered to 12-year-olds, and

  • respiratory syncytial virus vaccine to be administered to infants and to 12-year-old females.

Four candidate vaccines fall into the favorable (III) category: those with which a vaccination strategy would incur moderate costs (more than $10,000 but less than $100,000) per QALY gained. The Level III vaccine candidates are as follows (in alphabetical order):

  • parainfluenza virus vaccine to be given to infants and to women in their first pregnancy,

  • rotavirus vaccine to be given to infants,

  • Group A streptococcus vaccine to be given to infants, and

  • Group B streptococcus vaccine to be given to high-risk adults and to either 12-year-old females or to women during first pregnancy (low utilization).

Seven candidate vaccines fall into the less favorable (IV) category: those with which a vaccination strategy would incur significant costs (more than $100,000 and up to well more than $1 million) per QALY gained. The Level IV vaccine candidates are as follows (in alphabetical order):

  • Borrelia burgdorferi vaccine to be given to resident infants born in and immigrants of any age to geographically defined high-risk areas,



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement